Stoke Therapeutics (STOK) CMO awarded 60,000 options and 40,000 RSUs

Rhea-AI Filing Summary

Ticho Barry reported acquisition or exercise transactions in this Form 4 filing.

Stoke Therapeutics’ chief medical officer, Barry Ticho, reported equity awards rather than open‑market trades. He was granted options to purchase 60,000 shares of common stock and 40,000 restricted stock units. The option vests monthly over four years starting March 15, 2026, while the RSUs vest in four annual tranches beginning February 15, 2027, in each case conditioned on continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$31.09	02/17/2026		A		60,000		(1)	02/16/2036	Common Stock	60,000	$0	60,000	D
Restricted Stock Units	(2)	02/17/2026		A		40,000		(3)	02/15/2030	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

3. The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Stoke Therapeutics (STOK) report for Barry Ticho?

Stoke Therapeutics reported that chief medical officer Barry Ticho received equity awards, not market trades. He was granted options on 60,000 shares and 40,000 restricted stock units, both subject to multi‑year vesting tied to his continued service with the company.

How many stock options were granted to Stoke Therapeutics CMO Barry Ticho?

Barry Ticho was granted options covering 60,000 shares of Stoke Therapeutics common stock. These options vest over 48 months, with 1/48 vesting on March 15, 2026 and another 1/48 vesting on each monthly anniversary, contingent on continued employment.

What are the terms of the restricted stock units granted to Barry Ticho at STOK?

Barry Ticho received 40,000 restricted stock units from Stoke Therapeutics. Each RSU represents a right to one share of common stock. The award vests in four equal annual installments, with the first 25% tranche vesting on February 15, 2027, subject to continued service.

Do the equity awards to Stoke Therapeutics’ CMO involve any purchase price?

The reported grants to Barry Ticho show a transaction price of $0.00 per unit, indicating they are compensatory awards. Value is realized only if vesting conditions are met and, for options, if the exercise price is favorable relative to future market prices.

Are Barry Ticho’s Stoke Therapeutics equity awards immediately vested?

The awards to Barry Ticho are not immediately vested. The options vest monthly over four years starting March 15, 2026, while the 40,000 RSUs vest 25% per year beginning February 15, 2027, in each case requiring his continued service at Stoke Therapeutics.